Abstract
1. The uptake of [3H]dopamine was measured using platelet-rich plasma (PRP) from neuroleptic- free subjects and again, in some cases, after the subject had been treated with neuroleptic drugs. 2. There were no differences in [3H]dopamine uptake by PRP in subjects who were or were not mentally ill. 3. After treatment with neuroleptic drugs the Km for platelet [3H]dopamine uptake had increased in 76% of subjects with schizophrenia and 87% of subjects with schizophreniform disorder. Similarly, the Vmax for platelet [3H]dopamine uptake had increased in 81% of the subjects with schizophrenia and 86% of the subjects with schizophreniform disorder. 4. By contrast, the Km for platelet [3H]dopamine uptake had decreased in 94% of subjects who had a psychoses associated with an illness other than schizophrenia or schizophreniform disorder whilst the Vmax for platelet [3H]dopamine uptake also decreased by 94% in these subjects. 5. In subjects with psychoses, platelet [3H]dopamine uptake is differentially altered during euroleptic drug treatment depending on diagnosis.
Original language | English |
---|---|
Pages (from-to) | 45-55 |
Number of pages | 11 |
Journal | Progress in Neuro-Psychopharmacology and Biological Psychiatry |
Volume | 20 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Jan 1996 |
Externally published | Yes |
Keywords
- Dopamine
- Neuroleptic drugs
- Platelet
- Schizophrenia